News Story: Full Text
Sponsored By
Tocagen Clinical Trial
Please Click On The Above Banner For More Details

 

 


Click HERE to return to brain tumor news headlines
Braintumor Website

 

Six year survival after prolonged temozolomide treatment in a 30-year-old patient with glioblastoma.


Posted on: 11/12/2009

 

  Acta Neurol Belg. 2009 Sep;109(3):238-42.

Six year survival after prolonged temozolomide treatment in a 30-year-old patient with glioblastoma.

Poelen J, Prick MJ, Jeuken JW, Wesseling P, Bernsen HJ.

Dept. of Neurology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands. jpoelen@hotmail.com

Glioblastoma (GBM) is the most malignant primary brain tumour in adults. Since 2005 surgery followed by radiotherapy with concomitant Temozolomide (TMZ) is the standard care for patients with a GBM. Despite these improved treatment strategies, survival of GBM-patients remains poor; and there are very few patients who survive for a long time. Also there is no standard therapeutic strategy after six cycles of TMZ, and further treatment is at the physician's discretion. We report a case of a young patient with a glioblastoma who, not only showed dramatic clinical and radiological improvement after TMZ treatment but who now also (under continued TMZ therapy) survives over 6 years, with complete remission clinically and radiologically. Up till now there are no studies describing TMZ treatment in GBM patients for as long as 6 years.

  PMID: 19902821 [PubMed - in process]
  Related articles


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740